Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for direct intraperitoneal administration after surgical resection of macroscopic tumors, Radspherin targets micro-metastases in body cavities, particularly for peritoneal carcinomatosis from ovarian and colorectal cancers. Key features include high-power alpha radiation with short range and half-life, slow-degrading microparticles for regional retention of effective radiation dose, and avoidance of biological targeting complexities. The company operates a state-of-the-art GMP-certified manufacturing facility in Oslo for producing Radspherin to support multi-center clinical trials across Europe and North America. Ongoing clinical programs include completed Phase 1 and Phase 1/2a trials, and a randomized Phase 2 trial in the US, UK, and Europe. Founded in 2010 and headquartered in Oslo, Norway, Oncoinvent ASA plays a role in advancing targeted radiotherapies within the oncology sector.
NOK 47.60
NOK 2.40 (-4.80%)
Price from 10 days ago
The business is unprofitable at the operating level (-593.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 744.2% YoY with margins expanding 4617.7pp.
Negative free cash flow of -NOK 130M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 23M
▲ +744.2% YoY
Net Income (TTM)
-NOK 155M
▼ -10.6% YoY
Op. Margin
-593.35%
▲ +4617.7pp YoY
ROIC
-81.30%
▲ +10.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 130M
▼ -44.8% YoY
Op. Cash Flow (TTM)
-NOK 129M
▼ -45.8% YoY
Net Debt
-NOK 170M
Net Cash Position
Cash & Equiv.
NOK 173M
3Y CAGR: +600.6%
Continue Research
Oncoinvent ASA (ONCIN.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oncoinvent ASA scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Oncoinvent ASA scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -593.4% operating margin and a -81.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ONCIN.XOSL's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.